OverviewSuggest Edit
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
| Type | Public | |
| Founded | 2010 | |
| HQ | Cambridge, US | Map |
| Website | foundationmedicine.com |
Recent NewsAll News
- UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening
- Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players are GE Healthcare; Abbott Lab, Precision Biologics, Foundation Medicine, Illumina and IBM Watson
- UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine
- UPDATE 1-Roche to pay $2.4 bln to buy rest of Foundation Medicine
Key People/Management at Foundation Medicine
Michael J. Pellini
President & CEO & Board Director
Steven J. Kafka
Chief Business Officer
Alexis Borisy
Co - Founder & Chairman of the Board
Vincent A. Miller
SVP, Clinical Development
Foundation Medicine Office Locations
Foundation Medicine has offices in Cambridge, Morrisville and Palo Alto
Cambridge, US (HQ)
150 Second St
Morrisville, US
7010 Kit Creek Rd
Palo Alto, US
525 University Ave #100
Foundation Medicine Financials and Metrics
Foundation Medicine Revenue
Foundation Medicine's revenue was reported to be $152.90 m in FY, 2017
| USD | |
|---|---|
Revenue (Q2, 2018) | 38.7m |
Net income (Q2, 2018) | (33.4m) |
EBIT (Q2, 2018) | (32.1m) |
Market capitalization (31-Jul-2018) | 5.1b |
Closing stock price (31-Jul-2018) | 137.0 |
Cash (30-Jun-2018) | 53.4m |
Foundation Medicine's current market capitalization is $5.1 b.
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.2m | 11.5m | 14.5m | 16.4m | 19.3m | 22.5m | 25.4m | 30.4m | 28.2m | 29.4m | 26.3m | 35.0m | 42.7m | 52.8m | 38.7m |
Cost of goods sold | 2.9m | 5.3m | 6.6m | 7.5m | 8.9m | 9.0m | 9.1m | 10.0m | 11.5m | 14.7m | 17.1m | ||||
Gross profit | 5.4m | 6.2m | 7.9m | 8.9m | 10.4m | 13.5m | 16.3m | 20.4m | 16.8m | 14.7m | 9.2m | ||||
Gross profit Margin, % | 65% | 54% | 54% | 54% | 54% | 60% | 64% | 67% | 59% | 50% | 35% |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 137.9m | 110.3m | 97.1m | 86.7m | 61.7m | 263.6m | 250.2m | 86.1m | 62.3m | 77.8m | 49.1m | 36.5m | 76.8m | 60.3m | 53.4m |
Accounts Receivable | 4.4m | 8.0m | 6.1m | 6.0m | 10.7m | 10.0m | 10.1m | 8.2m | 10.4m | 6.9m | 5.9m | 13.6m | 13.3m | 32.2m | 40.9m |
Prepaid Expenses | 950.0k | 1.3m | 1.2m | 1.5m | 4.0m | 5.7m | 6.1m | 5.1m | 3.8m | 3.0m | 5.3m | 5.1m | 4.6m | 13.0m | |
Inventories | 942.0k | 3.0m | 2.6m | 4.2m | 4.5m | 6.1m | 9.5m | 6.7m | 10.2m | 12.0m | 10.3m | 8.9m | 10.4m | 16.4m | 25.8m |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (29.9m) | (12.2m) | (25.9m) | (38.9m) | (17.0m) | (50.0m) | (70.6m) | (17.3m) | (46.3m) | (77.6m) | (46.5m) | (90.7m) | (123.4m) | (37.4m) | (70.8m) |
Depreciation and Amortization | 3.2m | 1.9m | 4.0m | 6.1m | 2.2m | 4.6m | 7.5m | 3.1m | 7.2m | 11.5m | 4.5m | 8.8m | 13.5m | 5.4m | 10.7m |
Inventories | (139.0k) | (1.2m) | (830.0k) | (2.4m) | 316.0k | (1.4m) | (4.8m) | 1.2m | (2.2m) | (4.0m) | 178.0k | 1.7m | 186.0k | (3.2m) | (12.7m) |
Accounts Payable | 530.0k | (3.3m) | (2.1m) | 1.4m | (991.0k) | (1.5m) | 4.3m | 2.6m | 4.8m | 5.6m | 278.0k | 4.4m | 5.7m | 3.5m | 3.6m |
- Source: SEC Filings
| USD | Y, 2018 |
|---|---|
Financial Leverage | -22.7 x |
Foundation Medicine Operating Metrics
Foundation Medicine's Customers was reported to be 30 in FY, 2016.
| FY, 2016 | |
|---|---|
Customers | 30 |
Facilities | 4 |
Products | 5 |
Foundation Medicine Revenue Breakdown
Foundation Medicine revenue breakdown by geographic segment: 91.2% from United States and 8.8% from Other
Foundation Medicine Online and Social Media Presence
7.69k Twitter followers
Foundation Medicine has 7.69k Twitter Followers. The number of followers has increased 2.3% month over month and increased 3.6% quarter over quarter
Foundation Medicine's Trends
Twitter Engagement Stats for @FoundationATCG
1.9k
Tweets
741
Following
7.7k
Followers
8
Tweets last 30 days
5.1
Avg. likes per Tweet
100%
Tweets with engagement
Foundation Medicine News and Updates
May 29, 2019
UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening
* Genetic sequencing test seen as vital to secure market
uptake
November 16, 2018
Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players are GE Healthcare; Abbott Lab, Precision Biologics, Foundation Medicine, Illumina and IBM Watson
DUBLIN, Nov. 16, 2018 /PRNewswire/ -- The "Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, And Segment Forecasts, 2018 - 2025" report has been added to...
June 19, 2018
UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine
* Echoes past biotech buy-outs at Flat Iron and Genentech
(Adds more on personalised cancer care, analyst comment)
June 19, 2018
UPDATE 1-Roche to pay $2.4 bln to buy rest of Foundation Medicine
ZURICH, June 19 (Reuters) - Swiss drugmaker Roche Holding AG
has agreed to pay $137 per share to buy the rest of
Foundation Medicine (FMI), a $2.4 billion transaction
that values the U.S. genomic profiling group at $5.3 billion,
the partners said on Tuesday.
Foundation Medicine Blogs
January 13, 2020
Partnerships Are Paving the Way for Improved Patient Options
This article was originally published on LinkedIn.
Over the past ten years, there has been a fundamental shift in the way cancer is being treated. Access…
December 20, 2019
A Year of Change and an Exciting Chapter Ahead
This article was originally published on LinkedIn.
December is always a busy time. Suddenly everyone seems to be filled with a sense of urgency and purpose…
December 07, 2019
ASH 2019: Can Rapid Precision Medicine Help Older Adults With AML?
When someone is diagnosed with acute myeloid leukemia (AML), doctors typically initiate treatment within 24-48 hours of diagnosis given the aggressive nature of the disease.
December 04, 2019
Breast cancer – a very personal history and an even more personalized future
This article was originally published on LinkedIn.
As I sat down to write this latest post, I was suddenly struck by how little I have written…
November 21, 2019
CTOS 2019: Navigating the sarcoma maze with CGP
Every cancer presents its challenges, but sarcomas are particularly troublesome. They are tricky to diagnose and have few treatment options.
Sarcomas are a group of rare…
October 11, 2019
ESMO 2019: Comprehensive Genomic Profiling Leverages Data Insights to Improve Patient Care
As scientists worldwide continue to pioneer breakthroughs and change the way we understand and treat advanced cancer, it’s important to stay connected so we can…
Foundation Medicine Frequently Asked Questions
When was Foundation Medicine founded?
Foundation Medicine was founded in 2010.
Who are Foundation Medicine key executives?
Foundation Medicine's key executives are Michael J. Pellini, Steven J. Kafka and Alexis Borisy.
How many employees does Foundation Medicine have?
Foundation Medicine has 535 employees.
What is Foundation Medicine revenue?
Latest Foundation Medicine annual revenue is $152.9 m.
What is Foundation Medicine revenue per employee?
Latest Foundation Medicine revenue per employee is $285.8 k.
Who are Foundation Medicine competitors?
Competitors of Foundation Medicine include Flatiron Health, Myriad Genetics and Boston Health Economics.
Where is Foundation Medicine headquarters?
Foundation Medicine headquarters is located at 150 Second St, Cambridge.
Where are Foundation Medicine offices?
Foundation Medicine has offices in Cambridge, Morrisville and Palo Alto.
How many offices does Foundation Medicine have?
Foundation Medicine has 3 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies